Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

IRIDEX stock

IRIX
US4626841013
912341

Price

1.74
Today +/-
+0.15
Today %
+9.64 %

IRIDEX stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the IRIDEX stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the IRIDEX stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the IRIDEX stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze IRIDEX's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

IRIDEX Stock Price History

DateIRIDEX Price
12/24/20241.74 undefined
12/23/20241.58 undefined
12/20/20241.64 undefined
12/19/20241.71 undefined
12/18/20241.64 undefined
12/17/20241.68 undefined
12/16/20241.71 undefined
12/13/20241.72 undefined
12/12/20241.72 undefined
12/11/20241.72 undefined
12/10/20241.74 undefined
12/9/20241.79 undefined
12/6/20241.79 undefined
12/5/20241.73 undefined
12/4/20241.85 undefined
12/3/20241.88 undefined
12/2/20241.90 undefined
11/29/20241.79 undefined
11/27/20241.80 undefined
11/26/20241.77 undefined

IRIDEX Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into IRIDEX, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by IRIDEX from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects IRIDEX’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of IRIDEX. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into IRIDEX’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing IRIDEX’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on IRIDEX’s growth potential.

IRIDEX Revenue, EBIT and net profit per share

DateIRIDEX RevenueIRIDEX EBITIRIDEX Net Income
2026e70.21 M undefined-5.27 M undefined-5.99 M undefined
2025e53.35 M undefined-5 M undefined-4.58 M undefined
2024e50.59 M undefined-8.36 M undefined-8.83 M undefined
202351.87 M undefined-10.01 M undefined-9.57 M undefined
202256.97 M undefined-7.54 M undefined-7.55 M undefined
202153.9 M undefined-7.53 M undefined-5.23 M undefined
202036.35 M undefined-6.58 M undefined-6.33 M undefined
201943.45 M undefined-8.97 M undefined-8.81 M undefined
201842.6 M undefined-12.87 M undefined-12.81 M undefined
201741.59 M undefined-13.03 M undefined-12.87 M undefined
201646.16 M undefined-2.45 M undefined-11.71 M undefined
201541.76 M undefined290,000 undefined470,000 undefined
201442.81 M undefined2.59 M undefined10.04 M undefined
201338.27 M undefined2.16 M undefined2.23 M undefined
201233.86 M undefined-860,000 undefined1.44 M undefined
201133.16 M undefined660,000 undefined2.61 M undefined
201032.31 M undefined1.19 M undefined3.05 M undefined
200931.03 M undefined1.23 M undefined2.59 M undefined
200848.53 M undefined-2.18 M undefined-7.37 M undefined
200755.53 M undefined-9.43 M undefined-22.27 M undefined
200635.9 M undefined-4.77 M undefined-5.75 M undefined
200537.03 M undefined1.81 M undefined1.67 M undefined
200432.81 M undefined-1.08 M undefined-400,000 undefined

IRIDEX Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
2457812182326322730313237355548313233333842414641424336535651505370
-100.0025.0040.0014.2950.0050.0027.7813.0423.08-15.6311.113.333.2315.63-5.4157.14-12.73-35.423.233.13-15.1510.53-2.3812.20-10.872.442.38-16.2847.225.66-8.93-1.966.0032.08
50.0050.0060.0057.1475.0058.3355.5656.5253.8556.2548.1543.3345.1643.7548.6551.4343.6439.5848.3950.0048.4848.4847.3750.0046.3443.4836.5940.4839.5341.6741.5144.6441.1842.0039.6230.00
123467101314181313141418182419151616161821192015171715222521000
-1001112112-10001-5-22-723212100-11-12-12-8-6-5-7-9-8-4-5
------100.00-50.00-100.00-150.00-----600.00340.00-68.18-128.5750.00-33.33-50.00100.00400.00--9.09--33.33-25.00-16.6740.0028.57-11.11-50.0025.00
1.371.374.254.244.356.416.766.776.857.296.766.937.077.27.887.718.298.829.9410.1310.238.9410.110.3610.1310.1711.5612.213.7113.8415.4215.9416.13000
------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The IRIDEX Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the IRIDEX is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220222023
                                                             
0.681.2315.1113.4910.8813.1512.999.111.5416.2913.721.4321.055.815.319.388.3510.7911.913.4413.31023.7521.7121.1912.6511.6323.8523.8513.927.03
1.922.485.396.067.618.268.018.078.046.557.46.596.058.888.27.485.465.555.487.358.349.2810.037.869.089.327.296.616.616.236.73
0000000000000000000000000003.113.113.542.93
0.641.261.863.986.57.269.7212.5610.738.728.928.599.515.9711.6495.636.668.0410.619.1211.1111.649.388.798.175.717.617.6110.619.91
0.71.090.6410.960.440.810.61.841.92.622.311.264.850.540.476.946.51.640.582.140.390.450.50.550.40.731.071.071.470.86
3.946.062324.5325.9529.1131.5330.3332.1533.4632.6438.9237.8635.5125.6926.3326.3829.527.0631.9832.930.7845.8739.4539.6130.5425.3642.2542.2535.7727.45
0.080.250.662.132.272.141.91.540.950.850.851.111.091.620.830.490.340.330.480.540.741.11.531.41.223.491.882.992.992.132.98
00000000004.3200000000000000000000
0000000000000000000000000000000
00000.1000000005.941.471.150.820.750.550.330.280.270.130.120.10.080.072.212.211.981.64
00000000000003.24000.470.530.530.530.530.530.530.530.530.530.530.970.970.970.97
0.40.10.050.030.071.521.591.921.181.521.271.071.220.350.230.321.221.040.290.37.379.150.080.140.20.150.130.270.271.461.4
0.480.350.712.162.443.663.493.462.132.376.442.182.3111.152.531.962.852.651.851.78.9211.052.272.192.054.252.616.446.436.546.99
4.426.4123.7126.6928.3932.7735.0233.7934.2835.8339.0841.140.1746.6628.2228.2929.2332.1528.9133.6841.8241.8348.1441.6441.6634.7927.9748.6948.6942.3134.44
                                                             
30406070707070707070708080100100100100100100100110110120130150150150170168170172
5.245.4921.2521.5521.822.1222.6923.4223.6323.925.2826.3329.738.739.1139.8241.1742.0338.9640.6738.5137.9955.1659.3971.5573.0974.1885.2685.2686.888.44
-1.84-0.840.172.274.015.328.056.776.927.36.898.562.81-19.46-26.83-24.25-21.2-18.59-17.15-14.92-4.88-4.41-16.12-28.99-41.8-50.62-56.94-62.17-62.17-69.72-79.04
000010010000-40-300-90-190-210-210-400000007080-205045-20-52
0000000000000000000000000000000
3.434.6921.4823.8925.8927.5130.8230.2630.6231.2732.234.9432.5919.2512.1915.4619.8623.521.9125.8533.7433.6939.1630.5329.9722.717.3723.3123.317.239.52
0.140.290.540.750.881.131.411.180.661.031.231.091.832.892.421.871.511.582.112.281.762.221.991.722.522.591.152.772.773.864.5
0.661.121.181.481.62.512.572.452.62.654.383.874.7811.535.165.3233.333.13.953.63.514.525.565.464.874.464.534.535.034.67
00.280.510.570.011.620.550.330.821.331.691.621.423.552.912.414.6941.161.131.681.71.953.112.532.311.835.355.353.573.81
0.180000000000009.8863.52000000000000000
00.010.01000000000000000000000001.250000
0.981.72.242.82.495.264.533.964.085.017.36.588.0327.8516.4913.129.28.916.377.367.047.438.4610.3910.519.778.6912.6512.6512.4612.97
0.020.010000000000000000000000001.250000
0000000000000000000000000000000
0000000000000000.150.60.810.640.461.040.70.520.731.212.330.6712.7412.7412.6111.94
0.020.0100000000000000.150.60.810.640.461.040.70.520.731.212.331.9212.7412.7412.6111.94
11.712.242.82.495.264.533.964.085.017.36.588.0327.8516.4913.279.89.727.017.828.088.138.9811.1211.7212.110.6125.3925.3925.0724.91
4.436.423.7226.6928.3832.7735.3534.2234.736.2839.541.5240.6247.128.6828.7329.6633.2228.9233.6741.8241.8248.1441.6541.6934.827.9848.748.6942.334.44
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of IRIDEX provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand IRIDEX's financial health and stability.

Assets

IRIDEX's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that IRIDEX must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of IRIDEX after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into IRIDEX's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1993199419951996199719981999nullnull20002001200220032004nullnull20052006200720082009null2010nullnull20112012201320142015nullnull20162017201820192020202120222022
0111211112-1000001-5-22-72-7323212100100-11-12-12-8-6-5-5-7
0000000000000000003303000000000000000000
0-100000000000000020000000000-800080000000
000-2-2-41-41-3-31404000-1-30-3-10-1-1-2-30-20-2060-111313-4
00000000000001010119727121101202022111001
0000000000000000000000000000000000000000
0000000002000000000000000000000000000000
000-10-12-120-3250502-1006036330040400-3-10-7-388-9
0000-1000000000000000000000000000-10000000
000-1-4-20-200-11-4-2-4-2-18-26000000030-1-1-1-1-10000-5-50
000-1-2-11-110-12-3-1-3-1-18-25000000040000000000-5-50
0000000000000000000000000000000000000000
0000000000000000009-3-1-3-2-1-2000000000002000
000150000000001010150000000-21-30-30152100010100
0001500000000010101110-20-3-2-30-21-3-1-3-11521002990
000000000000000000-3303-10-1000000000000000
0000000000000000000000000000000000000000
00012-4-43-430-54101028-150300302110-30-313-20-8-11212-9
-0.360.710.66-1.9-1.93-2.872.2700-0.72-4.132.244.490.38002.43-1.91-1.47-0.326.4103.63002.85-0.830.393.44-1.4700-1.2-4.15-10.47-8.04-3.348.018-9.81
0000000000000000000000000000000000000000

IRIDEX stock margins

The IRIDEX margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IRIDEX. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IRIDEX.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the IRIDEX's sales revenue. A higher gross margin percentage indicates that the IRIDEX retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the IRIDEX's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the IRIDEX's total revenue generated. When comparing the revenue margin year over year, investors can gauge the IRIDEX's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the IRIDEX. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the IRIDEX's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

IRIDEX Margin History

IRIDEX Gross marginIRIDEX Profit marginIRIDEX EBIT marginIRIDEX Profit margin
2026e42.04 %-7.51 %-8.53 %
2025e42.04 %-9.37 %-8.59 %
2024e42.04 %-16.53 %-17.45 %
202342.04 %-19.29 %-18.45 %
202244.53 %-13.24 %-13.25 %
202142.36 %-13.97 %-9.7 %
202042.81 %-18.1 %-17.41 %
201941.29 %-20.64 %-20.28 %
201841.01 %-30.21 %-30.07 %
201737.27 %-31.33 %-30.94 %
201645.15 %-5.31 %-25.37 %
201547.77 %0.69 %1.13 %
201450.01 %6.05 %23.45 %
201348.58 %5.64 %5.83 %
201248.29 %-2.54 %4.25 %
201149.13 %1.99 %7.87 %
201050.14 %3.68 %9.44 %
200949.76 %3.96 %8.35 %
200840.55 %-4.49 %-15.19 %
200743.72 %-16.98 %-40.1 %
200652.4 %-13.29 %-16.02 %
200549.1 %4.89 %4.51 %
200445.38 %-3.29 %-1.22 %

IRIDEX Stock Sales Revenue, EBIT, Earnings per Share

The IRIDEX earnings per share therefore indicates how much revenue IRIDEX has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IRIDEX earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IRIDEX's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IRIDEX’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IRIDEX's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

IRIDEX Revenue, EBIT and net profit per share

DateIRIDEX Sales per ShareIRIDEX EBIT per shareIRIDEX Earnings per Share
2026e4.22 undefined0 undefined-0.36 undefined
2025e3.21 undefined0 undefined-0.28 undefined
2024e3.04 undefined0 undefined-0.53 undefined
20233.22 undefined-0.62 undefined-0.59 undefined
20223.57 undefined-0.47 undefined-0.47 undefined
20213.5 undefined-0.49 undefined-0.34 undefined
20202.63 undefined-0.48 undefined-0.46 undefined
20193.17 undefined-0.65 undefined-0.64 undefined
20183.49 undefined-1.05 undefined-1.05 undefined
20173.6 undefined-1.13 undefined-1.11 undefined
20164.54 undefined-0.24 undefined-1.15 undefined
20154.12 undefined0.03 undefined0.05 undefined
20144.13 undefined0.25 undefined0.97 undefined
20133.79 undefined0.21 undefined0.22 undefined
20123.79 undefined-0.1 undefined0.16 undefined
20113.24 undefined0.06 undefined0.26 undefined
20103.19 undefined0.12 undefined0.3 undefined
20093.12 undefined0.12 undefined0.26 undefined
20085.5 undefined-0.25 undefined-0.84 undefined
20076.7 undefined-1.14 undefined-2.69 undefined
20064.66 undefined-0.62 undefined-0.75 undefined
20054.7 undefined0.23 undefined0.21 undefined
20044.56 undefined-0.15 undefined-0.06 undefined

IRIDEX business model

IRIDEX Corp is a global medical technology company that specializes in the development, manufacturing, marketing, and distribution of innovative laser-based medical devices and services. The company was originally founded in 1989 and is headquartered in Mountain View, California. IRIDEX's business model is divided into various divisions, each serving different markets. The divisions include ophthalmology, otolaryngology (ENT), gynecology and urology, as well as scientific research. The company offers a wide range of high-tech laser systems that can be used to treat various conditions, such as retinal diseases, glaucoma, nasal and throat disorders, gynecological and urological conditions, and other medical applications. One of the most well-known divisions of IRIDEX is ophthalmology, which offers a wide range of laser systems for the treatment of retinal diseases. These retinal diseases include diabetic retinopathy, retinal edema, age-related macular degeneration, and retinal detachment. The company also has a high-tech system called Cyclo G6TM, which is used for the treatment of glaucoma. This system can also be used in conjunction with other devices, such as ultrasound systems, for optimized clinical effectiveness. The ENT division offers laser systems for the treatment of nasal and throat disorders, such as snoring, polyps, stenosis, and tumors. The range of laser systems varies from simple systems to advanced systems that can be connected to a flexible endoscope for more precise treatment. IRIDEX's gynecology and urology division offers laser systems for various applications, such as urinary incontinence, bladder problems, tumor removal, prostate tissue removal, and medical treatments to improve sexual function. Laser systems can also be used in combination with other medical devices, such as ultrasound systems. The company places great emphasis on scientific research and development to create and introduce innovative technologies to the market. Therefore, IRIDEX collaborates closely with various research institutes, universities, and medical professionals to further develop its technological advances. The company is also committed to providing comprehensive training and support to its customers to ensure that they use the devices safely and effectively. Overall, IRIDEX Corp has established itself as an innovative and powerful multinational company in the field of medical technology. The company is constantly striving to expand its range of products and services and impress its customers with its high-quality solutions. IRIDEX is confident that it will continue to play a significant role in the medical technology industry in the future. IRIDEX is one of the most popular companies on Eulerpool.com.

IRIDEX SWOT Analysis

Strengths

IRIDEX Corp is a leading global provider of innovative laser-based medical solutions. Their cutting-edge technology and expertise in ophthalmology have positioned them as a trusted brand in the industry.

The company's strong intellectual property portfolio gives them a competitive advantage and protects their innovations from being easily replicated by competitors.

IRIDEX Corp has established a strong distribution network worldwide, enabling them to reach a wide customer base and expand their market presence.

Weaknesses

The company heavily relies on a limited number of key customers for a significant portion of their revenue, making them vulnerable to changes in customer demand and potential loss of key accounts.

IRIDEX Corp faces intense competition from well-established players in the medical device industry. Their ability to differentiate themselves and maintain market share can be challenging.

As a technology-driven company, IRIDEX Corp is exposed to the risk of rapid technological advancements that could render their current products obsolete or less competitive.

Opportunities

The global demand for minimally invasive medical treatments is growing, presenting an opportunity for IRIDEX Corp to expand their market and offer their advanced laser-based solutions to a broader range of medical specialties.

Advancements in healthcare infrastructure and access to medical services in emerging markets provide IRIDEX Corp with an opportunity to tap into new geographical regions and increase their customer base.

The increasing prevalence of ocular diseases, such as glaucoma and diabetic retinopathy, presents a significant market opportunity for IRIDEX Corp to address unmet medical needs and develop targeted treatments.

Threats

IRIDEX Corp operates in a highly regulated industry, subject to rigorous compliance requirements. Any failure to comply with regulations and standards could result in legal and financial consequences.

The ongoing COVID-19 pandemic poses a threat to the company's operations, as it has disrupted global healthcare systems and caused delays in elective surgeries, leading to a potential decrease in demand for their products.

Intense competition and the potential entry of new players in the market pose a threat to IRIDEX Corp's market share and profitability.

IRIDEX Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

IRIDEX Revenue by Segment

Segmente20222022202120192018
Retina31.11 M USD31.66 M USD18.09 M USD22.88 M USD-
Other8.85 M USD10.62 M USD6.99 M USD7.5 M USD-
Cyclo G613.95 M USD14.69 M USD---
G6--11.27 M USD13.07 M USD-
Recurring revenues----22.59 M USD
Systems----20.01 M USD

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

IRIDEX Revenue by Segment

Segmente20222022202120192018
Service Contract Revenues1.39 M USD1.51 M USD1.26 M USD1.36 M USD1.32 M USD

IRIDEX Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

IRIDEX Revenue by Segment

DateAmericas, excluding the U.SAsia pacific rimAsia/Pacific RimEuropeEurope, Middle East and AfricaRest of AmericasUnited States
20222.54 M USD-12.23 M USD13.57 M USD--25.56 M USD
20223.06 M USD-10.93 M USD-13.8 M USD-29.18 M USD
20211.97 M USD-7.06 M USD8.01 M USD--19.31 M USD
20192.86 M USD-8.43 M USD9.89 M USD--22.27 M USD
20182.59 M USD-8.17 M USD9.74 M USD--22.1 M USD
2017--8.16 M USD8.1 M USD-2.32 M USD23.02 M USD
2016--7.16 M USD7.97 M USD-2.68 M USD23.95 M USD
2016--8.62 M USD9.57 M USD-2.8 M USD25.17 M USD
2015--7.93 M USD9.1 M USD-3.2 M USD22.59 M USD
2013-6.58 M USD-7.35 M USD-3.31 M USD21.04 M USD
2012-------
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

IRIDEX Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

IRIDEX historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

IRIDEX shares outstanding

The number of shares was IRIDEX in 2023 — This indicates how many shares 16.128 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IRIDEX earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IRIDEX's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IRIDEX’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IRIDEX's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for IRIDEX.

IRIDEX latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.09 -0.12  (-30.72 %)2024 Q3
6/30/2024-0.12 -0.16  (-30.72 %)2024 Q2
3/31/2024-0.12 -0.21  (-71.57 %)2024 Q1
12/31/2023-0.05 -0.18  (-252.94 %)2023 Q4
9/30/2023-0.13 -0.11  (13.73 %)2023 Q3
6/30/2023-0.11 -0.17  (-51.52 %)2023 Q2
3/31/2023-0.12 -0.13  (-6.21 %)2023 Q1
12/31/2022-0.11 -0.07  (37.61 %)2022 Q4
9/30/2022-0.15 -0.11  (25.63 %)2022 Q3
6/30/2022-0.16 -0.14  (11.45 %)2022 Q2
1
2
3
4
5
...
8

IRIDEX shareholders

%
Name
Stocks
Change
Date
9.68823 % Topcon Corp1,612,12204/1/2024
6.44360 % Stanley Manne Trust1,072,21504/1/2024
6.00962 % Paragon JV Partners, LLC1,000,00006/30/2024
3.37197 % The Vanguard Group, Inc.561,09606/30/2024
2.76923 % AMH Equity, Ltd.460,8004,4006/30/2024
2.43365 % Renaissance Technologies LLC404,960-5,2006/30/2024
0.98376 % Mercer (Patrick)163,697-2,0737/4/2024
0.77579 % Geode Capital Management, L.L.C.129,0928,3986/30/2024
0.72618 % Grove (Robert Earle)120,836-11,7954/1/2024
0.68248 % ARS Investment Partners LLC113,56509/30/2024
1
2
3
4
5
...
6

IRIDEX Executives and Management Board

Mr. David Bruce

(63)
IRIDEX President, Chief Executive Officer, Director (since 2018)
Compensation 765,765

Mr. Patrick Mercer

(51)
IRIDEX Chief Operating Officer
Compensation 568,013

Mr. Fuad Ahmad

(53)
IRIDEX Interim Chief Financial Officer
Compensation 424,900

Ms. Beverly Huss

(63)
IRIDEX Independent Director
Compensation 156,650

Mr. Scott Shuda

(57)
IRIDEX Independent Chairman of the Board
Compensation 148,059
1
2

IRIDEX Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Alcon Stock
Alcon
SupplierCustomer0,22-0,270,450,640,250,67
Canon Stock
Canon
SupplierCustomer-0,12-0,89-0,66-0,71-0,700,58
Menicon Stock
Menicon
SupplierCustomer-0,280,720,810,790,890,55
1

Most common questions regarding IRIDEX

What values and corporate philosophy does IRIDEX represent?

IRIDEX Corp represents values of innovation, excellence, and patient-centricity. With a corporate philosophy centered around advancing patient care, IRIDEX Corp is committed to delivering cutting-edge medical solutions for eye diseases. The company strives to improve outcomes and enhance the quality of life for patients through the development and commercialization of minimally invasive laser-based medical devices. By combining state-of-the-art technology and a patient-first approach, IRIDEX Corp aims to revolutionize the treatment of retinal diseases and glaucoma. Through its commitment to innovation and dedication to improving patient outcomes, IRIDEX Corp has established itself as a leading player in the ophthalmic medical device industry.

In which countries and regions is IRIDEX primarily present?

IRIDEX Corp is primarily present in the United States.

What significant milestones has the company IRIDEX achieved?

IRIDEX Corp has achieved numerous significant milestones over the years. The company has successfully emerged as a leading provider of laser-based medical solutions, specializing in treating sight-threatening eye conditions. Notably, IRIDEX Corp introduced the innovative MicroPulse technology, which revolutionized the way retinal diseases are treated. Additionally, the company has expanded its product portfolio and global presence. IRIDEX Corp's dedication to technological advancements and commitment to enhancing patient outcomes have contributed to its position as a trusted name in ophthalmic healthcare.

What is the history and background of the company IRIDEX?

IRIDEX Corp is a renowned medical technology company specializing in the development and commercialization of innovative laser systems for the treatment of various eye diseases. Founded in 1989, IRIDEX has since garnered a strong reputation for its cutting-edge products and advanced therapeutic solutions. The company boasts a rich history, marked by significant milestones and achievements in the field of ophthalmology. Guided by a commitment to revolutionize the way eye diseases are diagnosed and treated, IRIDEX remains at the forefront of the industry, continually striving to enhance patient outcomes through its state-of-the-art technologies.

Who are the main competitors of IRIDEX in the market?

The main competitors of IRIDEX Corp in the market are Alcon Inc., Ellex Medical Lasers Ltd., and Lumenis Ltd.

In which industries is IRIDEX primarily active?

IRIDEX Corp is primarily active in the medical technology industry.

What is the business model of IRIDEX?

The business model of IRIDEX Corp focuses on developing, manufacturing, and marketing medical laser systems and delivery devices for the treatment of eye diseases and conditions. With a comprehensive portfolio of products, the company aims to provide innovative solutions to both ophthalmologists and patients. By leveraging its cutting-edge laser technology, IRIDEX Corp aims to improve the standards of care and enhance patient outcomes in the field of ophthalmology.

What is the P/E ratio of IRIDEX 2024?

The IRIDEX P/E ratio is -3.18.

What is the P/S ratio of IRIDEX 2024?

The IRIDEX P/S ratio is 0.55.

What is the Quality Investing of IRIDEX?

The Quality Investing for IRIDEX is 3/10.

What is the revenue of IRIDEX 2024?

The expected IRIDEX revenue is 50.59 M USD.

How high is the profit of IRIDEX 2024?

The expected IRIDEX profit is -8.83 M USD.

What is the business model of IRIDEX

IRIDEX Corporation is a leading company specializing in the development, manufacture, and sale of medical laser systems and accessories. The company offers a wide range of products and services targeting various customers including doctors, ophthalmologists, medical device providers, and surgical centers worldwide. The company specializes in two main divisions: ophthalmology and aesthetic dermatology. In the ophthalmology division, IRIDEX offers a variety of laser systems and system accessories focusing on the treatment of retinal diseases and glaucoma, as well as cosmetic and therapeutic procedures. The company is particularly known for its proven laser system, the "PASCAL Photocoagulator," which is considered one of the most advanced retinal laser therapy systems. IRIDEX's ophthalmology division also offers other innovative products such as the IRIS Medical SoftFit Gonioscope for glaucoma diagnosis. IRIDEX is also active in aesthetic dermatology, offering products for hair removal, wrinkle treatment, vascular treatment, and the treatment of common skin issues like acne. The flagship products in this area are the "GentleMAXPro" laser system and the multifunctional aesthetic system "Apogee+." The company generates revenue through the sale of devices and accessories, including consumables, as well as services such as training and support. IRIDEX sells its products in over 100 countries, targeting markets in Europe, North America, and Asia. It serves its customers directly through its subsidiaries or through distribution partners. The company's business model is based on a combination of research and development, marketing and sales, customer care, and efficiency assurance in production. IRIDEX engineers constantly work to improve the effectiveness and usability of their products, creating patient-oriented solutions based on scientifically proven results. IRIDEX has also entered into distribution agreements with global distributors to market and sell its products worldwide. IRIDEX aims to improve the standards and procedures of laser technology and continuously optimize patient care in the fields of ophthalmology and aesthetic dermatology. The company strives to build long-term relationships with clinicians and scientists to deliver advanced solutions in the medical device industry. In summary, IRIDEX is a company dedicated to advanced laser technology and accessories for ophthalmology and aesthetic dermatology. Through continuous innovation and collaborative partnerships, the company aims to support its customers with patient-oriented solutions. IRIDEX has already achieved significant milestones in its goal of establishing itself as the leading product line for global ophthalmology and aesthetic dermatology. IRIDEX Corporation is a leading company specialized in the development, manufacturing, and sale of medical laser systems and accessories. The company offers a wide range of products and services targeting various customers, including doctors, ophthalmologists, medical device providers, and surgical centers worldwide. The company is specialized in two main divisions: Ophthalmology and aesthetic dermatology. In the ophthalmology division, IRIDEX offers a variety of laser systems and system accessories focusing on the treatment of retinal diseases and glaucoma, as well as cosmetic and therapeutic procedures. The company is particularly known for its proven laser system, the "Pascal Photocoagulator," which is considered one of the most advanced retinal laser therapy systems. The IRIDEX ophthalmology division also offers other innovative products, such as the IRIS Medical SoftFit Gonioscope for glaucoma diagnosis. IRIDEX is also active in aesthetic dermatology, where it offers products for hair removal, wrinkle treatment, vascular treatment, and the treatment of common skin problems such as acne. The flagship products in this area are the "GentleMAXPro" laser system and the multifunctional aesthetic system "Apogee+." The company generates revenue through the sale of devices and accessory products, including consumables, and services such as training and support. IRIDEX sells its products in more than 100 countries, targeting markets in Europe, North America, and Asia. It serves its customers directly through its subsidiaries or through distribution partners. The company's business model is based on a combination of research and development, marketing and sales, customer support, and efficiency assurance in production. IRIDEX engineers constantly work to improve the effectiveness and usability of their products, creating patient-oriented solutions based on scientifically proven results. IRIDEX has also entered into distribution agreements with global distributors to market and sell its products worldwide. IRIDEX aims to improve the standards and procedures of laser technology and continuously optimize patient care in the fields of ophthalmology and aesthetic dermatology. The company strives to build long-term relationships with clinicians and scientists to deliver advanced solutions in the medical device industry. In summary, IRIDEX is a company dedicated to advanced laser technology and accessory products for ophthalmology and aesthetic dermatology. Through continuous innovation and collaborative partnerships, the company aims to support its customers with patient-oriented solutions. IRIDEX has already achieved significant milestones in its goal of establishing itself as a leading product line for global ophthalmology and aesthetic dermatology.

What is the IRIDEX dividend?

IRIDEX pays a dividend of 0 USD distributed over payouts per year.

How often does IRIDEX pay dividends?

The dividend cannot currently be calculated for IRIDEX or the company does not pay out a dividend.

What is the IRIDEX ISIN?

The ISIN of IRIDEX is US4626841013.

What is the IRIDEX WKN?

The WKN of IRIDEX is 912341.

What is the IRIDEX ticker?

The ticker of IRIDEX is IRIX.

How much dividend does IRIDEX pay?

Over the past 12 months, IRIDEX paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IRIDEX is expected to pay a dividend of 0 USD.

What is the dividend yield of IRIDEX?

The current dividend yield of IRIDEX is .

When does IRIDEX pay dividends?

IRIDEX pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IRIDEX?

IRIDEX paid dividends every year for the past 0 years.

What is the dividend of IRIDEX?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IRIDEX located?

IRIDEX is assigned to the 'Health' sector.

Wann musste ich die Aktien von IRIDEX kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IRIDEX from 12/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/25/2024.

When did IRIDEX pay the last dividend?

The last dividend was paid out on 12/25/2024.

What was the dividend of IRIDEX in the year 2023?

In the year 2023, IRIDEX distributed 0 USD as dividends.

In which currency does IRIDEX pay out the dividend?

The dividends of IRIDEX are distributed in USD.

All fundamentals about IRIDEX

Our stock analysis for IRIDEX Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IRIDEX Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.